A Phase 3 interventional study of Dabigatran etexilate and Warfarin in Thromboembolism, sponsored by Boehringer Ingelheim. Completed at 36 sites in 9 countries. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2019-08-15.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Thromboembolism by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Thromboembolism · Boehringer Ingelheim.
Among the 12 studies in Thromboembolism by Boehringer Ingelheim, this one is the only one that started in 2016, is one of 7 in phase 3, and was the 11th registered.
288 studies on the registry are indexed under Thromboembolism; 42 are open to participants now.
Browse Thromboembolism studies →None of the 12 studies in Thromboembolism by Boehringer Ingelheim is open now. The open studies under Thromboembolism, anywhere →
Of the 32 Thromboembolism studies recruiting now, 23 (72%) set no upper age limit and 4 (13%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2016.
This study's enrollment of 120 is below the median of 173 across 155 interventional studies indexed under Thromboembolism.
Median enrollment 2,577 across the 8 interventional studies, 239 across the 4 observational. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Thromboembolism by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, prospective, international, randomized (1:1), open-label study with two parallel groups. This phase III study is planned to investigate the efficacy and safety of dabigatran etexilate versus dose-adjusted warfarin on a net clinical benefit endpoint of major bleeding (ISTH criteria) and new venous thrombotic event (VTE) (primary endpoint) with blinded endpoint adjudication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dabigatran etexilate
Drug: Warfarin
Percentage of Participants With Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis (ISTH) Criteria in Full Observation Period.
Composite of the percentage of participants with MBE according to ISTH criteria and VTE (recurring cerebral venous thrombosis (CVT); deep venous thrombosis (DVT) of any limb, pulmonary embolism (PE), splanchnic vein thrombosis) in full observation period. All components were adjudicated in a blinded manner. Major bleeds were defined according to the ISTH definition of a major bleed, as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or * Bleeding associated with a reduction in haemoglobin of at least 2 grams/deciLitre (1.24 millimole/Litre) within 24 h, or leading to transfusion of 2 or more units of blood or packed cells and/or * Fatal bleed
Time frame: From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.
Percentage of Participants With Recurring Cerebral Venous and Dural Sinus Thrombosis; DVT of Any Limb, PE or Splanchnic Vein Thrombosis in Full Observation Period
VTE criterions: * New neurological signs/symptoms or worsening of previous signs/symptoms with new CVT on neuroimaging. * DVT of any limb was documented by: Abnormal compression ultrasonography; An intraluminal filling defect on venography; At autopsy * Splanchnic vein thrombosis: The presence of endoluminal material/absence of flow in the extrahepatic portal veins/mesenteric veins as shown by duplex-Doppler ultrasound/contrast-enhanced CT scan/MRI. * PE was documented by: An intraluminal filling defect in segmental/more proximal branches on spiral CT scan; An intraluminal filling defect/an extension of an existing defect/a sudden cut-off of vessels\>2.5 mm in diameter on the pulmonary angiogram; Perfusion defect of at least 75% of a segment with a local normal ventilation result on ventilation/perfusion lung scan; Inconclusive spiral CT, pulmonary angiography/lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasonography/venography; At autopsy.
Time frame: From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.
Cerebral Venous Recanalisation as Measured by the Change in Number of Occluded Cerebral Veins and Sinuses at Week 24
Cerebral venous recanalisation was assessed by imaging and was adjudicated. Occlusion of cerebral veins and sinuses was scored as: 1 = full occlusion; 0 = no occlusion/partial occlusion. This score was applied using the below conventions: Superior sagittal, straight, cavernous sinuses, left and right jugular veins each scored individually as either 0 or 1; Right lateral transverse and sigmoid sinus were scored together, Left lateral transverse and sigmoid sinus were scored together, Superior petrous sinus and inferior petrous sinus were scored together; Deep venous system, Superficial cortical veins, Cerebellar veins were scored as systems. For each patient a total score was calculated at baseline and at EOT and the recanalisation score was calculated as EOT - baseline total scores with conventions as 0 = no cerebral veins or sinuses fully occluded and 11 = all cerebral veins and sinuses fully occluded; the lower the score, the better.
Time frame: Baseline and week 24
Percentage of Participants With Major Bleeding According to ISTH Criteria in Full Observation Period
Major bleeds were defined according to the ISTH definition of a major bleed, as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or * Bleeding associated with a reduction in haemoglobin of at least 2 grams/deciLitre (1.24 millimole/Litre) within 24 h, or leading to transfusion of 2 or more units of blood or packed cells and/or * Fatal bleed
Time frame: From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.
Composite Endpoint of Percentage of Participants With New Intracranial Haemorrhage or Worsening of the Haemorrhagic Component of a Previous Lesion After up to 24 Weeks
Intracranial haemorrhage (ICH) comprised the subtypes of intracerebral bleeds, subdural bleeds, epidural bleeds and subarachnoid bleeds that were recorded.
Time frame: From first administration of trial medication until end of treatment visit, up to 24 weeks.
Percentage of Participants With Clinically Relevant Non-major Bleeding Events in Full Observation Period.
A clinically relevant non-major bleeding event (CRNMBE) was a clinically overt bleed that did not meet the criteria for a major bleed but prompted a clinical response, in that it led to at least 1 of the following: A hospital admission (i.e. overnight stay in the hospital) for bleeding / A physician guided medical or surgical treatment for bleeding / A physician guided change, interruption or discontinuation of trial medication.
Time frame: From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.
Percentage of Participants With Major Bleeding According to ISTH Criteria or CRNMBEs After up to 24 Weeks
Percentage of participants with major bleeding according to ISTH criteria or CRNMBEs after up to 24 weeks.
Time frame: From first administration of trial medication until end of treatment visit, up to 24 weeks.
Percentage of Participants With Any Bleeding Event After up to 24 Weeks
Percentage of participants with any bleeding event after up to 24 weeks where any bleeding event is the sum of all major and non-major bleeding events.
Time frame: From first administration of trial medication until end of treatment visit, up to 24 weeks.
This is a randomised, open-label, exploratory trial with blinded endpoint adjudication (PROBE \[prospective, randomised, open-label, blinded endpoint\] design), comparing efficacy and safety of oral dabigatran etexilate versus oral warfarin in patients with cerebral venous and dural sinus thrombosis over a 24-week period.
| Milestone | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Started | 60 | 60 |
| Completed | 59 | 58 |
| Not completed | 1 | 2 |
| Withdrew: Reason not listed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 |
Composite of the percentage of participants with MBE according to ISTH criteria and VTE (recurring cerebral venous thrombosis (CVT); deep venous thrombosis (DVT) of any limb, pulmonary embolism (PE), splanchnic vein thrombosis) in full observation period. All components were adjudicated in a blinded manner. Major bleeds were defined according to the ISTH definition of a major bleed, as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or * Bleeding associated with a reduction in haemoglobin of at least 2 grams/deciLitre (1.24 millimole/Litre) within 24 h, or leading to transfusion of 2 or more units of blood or packed cells and/or * Fatal bleed
| Percentage of participants | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Percentage of Participants With Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis (ISTH) Criteria in Full Observation Period. | 1.7 (0.0 to 8.9) | 3.3 (0.4 to 11.5) |
VTE criterions: * New neurological signs/symptoms or worsening of previous signs/symptoms with new CVT on neuroimaging. * DVT of any limb was documented by: Abnormal compression ultrasonography; An intraluminal filling defect on venography; At autopsy * Splanchnic vein thrombosis: The presence of endoluminal material/absence of flow in the extrahepatic portal veins/mesenteric veins as shown by duplex-Doppler ultrasound/contrast-enhanced CT scan/MRI. * PE was documented by: An intraluminal filling defect in segmental/more proximal branches on spiral CT scan; An intraluminal filling defect/an extension of an existing defect/a sudden cut-off of vessels\>2.5 mm in diameter on the pulmonary angiogram; Perfusion defect of at least 75% of a segment with a local normal ventilation result on ventilation/perfusion lung scan; Inconclusive spiral CT, pulmonary angiography/lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasonography/venography; At autopsy.
| Percentage of participants | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Recurring CVT | 0.0 (0.0 to 6.0) | 0.0 (0.0 to 6.0) |
| DVT of any limb | 0.0 (0.0 to 6.0) | 0.0 (0.0 to 6.0) |
| PE | 0.0 (0.0 to 6.0) | 0.0 (0.0 to 6.0) |
| Splanchnic vein thrombosis | 0.0 (0.0 to 6.0) | 0.0 (0.0 to 6.0) |
Cerebral venous recanalisation was assessed by imaging and was adjudicated. Occlusion of cerebral veins and sinuses was scored as: 1 = full occlusion; 0 = no occlusion/partial occlusion. This score was applied using the below conventions: Superior sagittal, straight, cavernous sinuses, left and right jugular veins each scored individually as either 0 or 1; Right lateral transverse and sigmoid sinus were scored together, Left lateral transverse and sigmoid sinus were scored together, Superior petrous sinus and inferior petrous sinus were scored together; Deep venous system, Superficial cortical veins, Cerebellar veins were scored as systems. For each patient a total score was calculated at baseline and at EOT and the recanalisation score was calculated as EOT - baseline total scores with conventions as 0 = no cerebral veins or sinuses fully occluded and 11 = all cerebral veins and sinuses fully occluded; the lower the score, the better.
| Units on scale | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Cerebral Venous Recanalisation as Measured by the Change in Number of Occluded Cerebral Veins and Sinuses at Week 24 | -0.8 ± 0.78 | -1.0 ± 0.92 |
Major bleeds were defined according to the ISTH definition of a major bleed, as follows: * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or * Bleeding associated with a reduction in haemoglobin of at least 2 grams/deciLitre (1.24 millimole/Litre) within 24 h, or leading to transfusion of 2 or more units of blood or packed cells and/or * Fatal bleed
| Percentage of participants | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Percentage of Participants With Major Bleeding According to ISTH Criteria in Full Observation Period | 1.7 (0.0 to 8.9) | 3.3 (0.4 to 11.5) |
Intracranial haemorrhage (ICH) comprised the subtypes of intracerebral bleeds, subdural bleeds, epidural bleeds and subarachnoid bleeds that were recorded.
| Percentage of participants | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Composite Endpoint of Percentage of Participants With New Intracranial Haemorrhage or Worsening of the Haemorrhagic Component of a Previous Lesion After up to 24 Weeks | 1.8 (0.0 to 9.6) | 3.8 (0.5 to 13.0) |
A clinically relevant non-major bleeding event (CRNMBE) was a clinically overt bleed that did not meet the criteria for a major bleed but prompted a clinical response, in that it led to at least 1 of the following: A hospital admission (i.e. overnight stay in the hospital) for bleeding / A physician guided medical or surgical treatment for bleeding / A physician guided change, interruption or discontinuation of trial medication.
| Percentage of participants | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Percentage of Participants With Clinically Relevant Non-major Bleeding Events in Full Observation Period. | 0.0 (0.0 to 6.0) | 1.7 (0.0 to 8.9) |
Percentage of participants with major bleeding according to ISTH criteria or CRNMBEs after up to 24 weeks.
| Percentage of participants | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Percentage of Participants With Major Bleeding According to ISTH Criteria or CRNMBEs After up to 24 Weeks | 1.7 (0.0 to 8.9) | 5.0 (1.0 to 13.9) |
Percentage of participants with any bleeding event after up to 24 weeks where any bleeding event is the sum of all major and non-major bleeding events.
| Percentage of participants | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Percentage of Participants With Any Bleeding Event After up to 24 Weeks | 20.0 (10.8 to 32.3) | 20.0 (10.8 to 32.3) |
Collected over From first administration of trial medication until 6 days after last administration of trial medication, up to 25 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate | 0/60 (0%) | 8/60 (13.3%) | 21/60 (35%) |
| Warfarin | 0/60 (0%) | 6/60 (10%) | 17/60 (28.3%) |
| Event | Dabigatran Etexilate | Warfarin |
|---|---|---|
| Subdural haematomaInjury, poisoning and procedural complications | 0/60 | 2/60 |
| PyelonephritisInfections and infestations | 0/60 | 1/60 |
| Severe fever with thrombocytopenia syndromeInfections and infestations | 0/60 | 1/60 |
| Urinary tract infectionInfections and infestations | 0/60 | 1/60 |
| MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/60 | 0/60 |
| Evans syndromeBlood and lymphatic system disorders | 1/60 | 0/60 |
| Cerebral haemorrhageNervous system disorders | 1/60 | 0/60 |
| Cerebral infarctionNervous system disorders | 1/60 | 0/60 |
| EpilepsyNervous system disorders | 1/60 | 0/60 |
| Intracranial aneurysmNervous system disorders | 1/60 | 0/60 |
| Event | Dabigatran Etexilate | Warfarin |
|---|---|---|
| HeadacheNervous system disorders | 10/60 | 8/60 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/60 | 0/60 |
| DiarrhoeaGastrointestinal disorders | 4/60 | 2/60 |
| DyspepsiaGastrointestinal disorders | 4/60 | 0/60 |
| DepressionPsychiatric disorders | 2/60 | 4/60 |
| InsomniaPsychiatric disorders | 0/60 | 4/60 |
Treated set (TS): The set includes patients who received at least one dose of study medication and were analysed according to the treatment they received.
| Age, Continuous(Years) | Dabigatran Etexilate | Warfarin | Total |
|---|---|---|---|
| Mean | 44.4 ± 14.06 | 46.0 ± 13.64 | 45.2 ± 13.82 |
| Sex: Female, Male(Participants) | Dabigatran Etexilate | Warfarin | Total |
|---|---|---|---|
| Female | 33 | 33 | 66 |
| Male | 27 | 27 | 54 |
| Ethnicity (NIH/OMB)(Participants) | Dabigatran Etexilate | Warfarin | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 11 | 15 |
| Not Hispanic or Latino | 52 | 43 | 95 |
| Unknown or Not Reported | 4 | 6 | 10 |
| Race (NIH/OMB)(Participants) | Dabigatran Etexilate | Warfarin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 12 | 7 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 45 | 49 | 94 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 4 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Jun 2018, 18 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran